Drugs / Quadrivalent Influenza Virus Split Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06800950 | Feb → Jul 2025 overdue | influenza | Institute of Medical Biology, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05138705 | Dec 2021 → Feb 2022 | influenza | Shanghai Institute Of Biological Products | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent Influenza Virus Split Vaccine | “Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose” NCT06800950 ↗ |
| Known as | Quadrivalent influenza vaccine | “0.5ml Quadrivalent influenza vaccine The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/ H3N2, B/Victoria and B/Yamagata strains” NCT05138705 ↗ |
| Modality | Vaccine | “Quadrivalent Influenza Virus Split Vaccine” NCT05138705 ↗ |